Navigation Links
Top Hepatitis C Treatments Equally Effective
Date:7/22/2009

Landmark assessment also finds treating early helps prevent liver failure

WEDNESDAY, July 22 (HealthDay News) -- A landmark hepatitis C virus study shows that the top two treatment options are equally effective and safe.

The long-awaited study, thought to be the largest of its kind, is important for the 180 million people worldwide -- 4 million in the United States -- who are infected with hepatitis C virus and at risk for liver scarring, organ failure and death.

Hepatitis C is America's leading cause of liver failure, liver cancer and liver transplantation. The disease is transmitted by contact with blood through sexual activities, drug use or personal care items.

The study of 3,070 adults at Johns Hopkins and 118 other U.S. medical centers showed that treating patients with either of the two standard antiviral therapies is safe and helps prevent liver damage.

The report appears online July 22 in the New England Journal of Medicine.

The drug therapies -- peginterferon alfa-2b plus ribavirin, or peginterferon alfa-2a plus ribavirin -- worked in 39.8 percent and 40.9 percent of patients, respectively. Commonly observed side effects included anemia, fatigue, headache, nausea, insomnia and depression.

The equality of the only two U.S. Food and Drug Administration-approved drug-treatment regimens for suppressing the virus surprised the researchers, according to a news release from Johns Hopkins.

"When considering treatments for hepatitis C infection, patients and their doctors now have solid evidence that they can weigh both antiviral therapies equally for effectiveness, safety and tolerability," Dr. Mark Sulkowski, medical director of the Johns Hopkins Center for Viral Hepatitis and the study's co-principal investigator, said in the news release.

While 10 percent to 13 percent of the study's participants quit the treatment because of side effects, Sulkowski said that was "within expectations for this type of therapy."

The researchers also found that the sooner patients get into treatment, the better.

"Treatment success is highly dependent on starting before liver cirrhosis has already set in, which can take from a year to decades," Sulkowski noted in the news release.

Evidence from the study also will help doctors learn more quickly whether the patient is responding to the drug therapy. This will allow patients to avoid side effects and the expense of taking unnecessary drugs.

The study was funded by the Schering-Plough Corp., the maker and provider of the study drugs ribavirin and peginterferon alfa-b.

More information

The U.S. Centers for Disease Control and Prevention has more information on hepatitis.



-- Dennis Thompson



SOURCE: Johns Hopkins University, news release, July 22, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Mass. General-based research center will investigate why immune system fails to control hepatitis C
2. New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report
3. Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
4. JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
5. Hepatitis C Virus Market Will Expand Dramatically From $2 Billion in 2008 to Nearly $7.7 Billion in 2013
6. Good news for some hard-to-treat hepatitis C patients
7. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
8. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
9. NEJM study points to new era in hepatitis C treatment
10. Resource for Those Living with Hepatitis C Announces Website Redesign
11. AUDIO from Medialink, Bayer Healthcare and Onyx Pharmaceuticals: Facts About Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Top Hepatitis C Treatments Equally Effective 
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: